R
RA Chem Pharma
Ra chem pharma limited and their merger with cohance lifesciences limited
About RA Chem Pharma
RA Chem Pharma Limited operates as a vertically integrated pharmaceutical entity based in Hyderabad, India, primarily engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs), finished dosage forms (FDF), and providing clinical research services. The company was founded in 2003 by J. Rajender Rao, Ravi K. Yerra, Sirish Kumar, and B. Srinivasa Reddy, who brought together their collective experience from different domains to establish the firm. Some records indicate an earlier incorporation date of 1996.
The company's business is structured across three main verticals: API and Intermediates, Formulations, and Clinical Research. This integrated model allows it to offer end-to-end services to its global client base, which includes major pharmaceutical companies in India and more than 40 other countries. The API division focuses on producing niche active ingredients and intermediates under cGMP conditions. The formulations division is a contract development and manufacturing partner for international clients, specializing in solid dosage forms like tablets and capsules with immediate and modified release mechanisms. Its clinical research and biosciences division conducts bioequivalence and bioavailability studies for a global clientele.
Historically, RA Chem Pharma has demonstrated significant growth. After being founded, it achieved substantial operational scale within a decade. A significant milestone occurred in 2017 when Micro Labs acquired a majority stake in the company. Subsequently, in July 2020, global private equity firm Advent International signed an agreement to acquire a controlling stake from Micro Labs, valuing the company at approximately ₹1,000 crore. This acquisition was part of Advent's strategy to build a leading API platform in India. Following this, in November 2022, RA Chem Pharma was amalgamated with its holding company and renamed Cohance Lifesciences Limited.
The company's manufacturing and research facilities hold multiple international accreditations, including approvals from the USFDA, UKMHRA, EMEA (Europe), and others. Its product portfolio is diverse, covering various therapeutic areas such as anti-depressants, anti-spasmodics, and anti-fungals, and also extends into niche markets like animal health and cosmeceuticals. The company serves both innovator and generic pharmaceutical players globally, leveraging a strong pipeline of Drug Master Files (DMFs) and Abbreviated New Drug Applications (ANDAs) to penetrate regulated markets.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| BUYOUT✓Exit | Jul 2020 | $134M | $134M | Advent International | — |
| EARLY VCEquity / VC | Apr 2017 | $11M | $44M | Undisclosed | — |
Growth signals
Latest recorded traffic for RA Chem Pharma is 650 monthly website visits, up 10.2% over the last three months. RA Chem Pharma's team declined 3.1% over the past year.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
RA Chem Pharma in the Hyderabad ecosystem
The RA Chem Pharma office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
Advent International
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about RA Chem Pharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See RA Chem Pharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.